{"id":15139,"date":"2024-12-16T20:45:56","date_gmt":"2024-12-16T13:45:56","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=15139"},"modified":"2024-12-16T20:45:56","modified_gmt":"2024-12-16T13:45:56","slug":"nona-biosciences-announces-discovery-collaboration-with-candid-therapeutics-for-next-generation-t-cell-engagers","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=15139","title":{"rendered":"Nona Biosciences Announces Discovery Collaboration with Candid Therapeutics for Next-Generation T-Cell Engagers"},"content":{"rendered":"\n\n\n
\"\"<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

CAMBRIDGE, Mass.<\/span><\/span>, Dec. 16, 2024<\/span><\/span> \/PRNewswire\/ — Nona Biosciences, a global biotechnology company providing a total solution from “Idea to IND” (I to ITM<\/sup>),\u00a0today\u00a0announced a research collaboration and license agreement to discover next-generation T-cell engagers (“TCEs”) with Candid Therapeutics, Inc. (“Candid”), a clinical-stage biotechnology company based in San Diego<\/span> and focused on becoming the leader in advancing TCEs for autoimmune diseases.<\/p>\n

\n<\/div>\n

Under the terms of the agreement, Nona Biosciences is eligible to receive up to $320 million<\/span>, including an upfront payment and potential milestone payments. Candid will be responsible for all further product development.<\/p>\n

“We are pleased to collaborate with Candid Therapeutics, a pioneer in advancing T-cell engagers for autoimmune diseases,” said Jingsong Wang<\/span>, MD, PhD, Chairman of Nona Biosciences. “T-cell engagers generated from our proprietary HBICE\u00ae<\/sup> technology platform offer several advantages, including precision targeting, flexible formats, enhanced efficacy and optimized safety profiles. Leveraging our industry-leading technology platforms, alongside our extensive expertise in antibody discovery and development, we look forward to supporting Candid in advancing innovative treatments and bringing new hope to patients.”<\/p>\n

“Nona Biosciences has an impressive discovery toolkit and we look forward to developing novel T-cell engagers through this collaboration,” said Ken Song<\/span>, MD, PhD, Chairman, President and CEO of Candid Therapeutics.<\/span><\/p>\n

About Nona Biosciences<\/b><\/p>\n

Nona Biosciences is a global biotechnology company committed to cutting edge technology innovation and providing a total solution from “Idea to IND” (I to ITM<\/sup>), ranging from target validation and antibody discovery through preclinical research. The integrated antibody and antibody-related discovery services with multiple modalities range from antigen preparation, animal immunization, single B cell screening, to antibody lead generation and engineering, developability assessment and pharmacological evaluation, leveraging advantages of Harbour Mice\u00ae<\/sup> platforms and the experienced therapeutic antibody discovery team.<\/p>\n

Harbour Mice\u00ae<\/sup> generates fully human monoclonal antibodies in classical two light and two heavy chain (H2L2) format, and heavy chain only (HCAb) format. Integrating Harbour Mice\u00ae<\/sup> and a single B cell cloning platform, Nona Biosciences is focused on driving global inventions of transformative next-generation drugs. For more information, please visit:\u00a0www.nonabio.com<\/a><\/u>.<\/p>\n

About Candid Therapeutics, Inc.<\/b><\/p>\n

Candid Therapeutics is a clinical-stage biotechnology company focused on becoming the leader in advancing T-cell engagers for B-cell depletion to treat autoimmune diseases. Candid is advancing two lead B-cell depleting TCE antibody drug candidates, with a goal to broadly explore the potential of TCEs across multiple autoimmune diseases by targeting different B-cell protein targets, as well as evaluating different depths of B-cell depletion. Established in 2024 and headquartered in San Diego, CA<\/span>, Candid is led by a team of entrepreneurial executives who have a track record of advancing programs into and through development and is supported by a distinguished syndicate of premier life science investors.<\/p>","protected":false},"excerpt":{"rendered":"

<\/p>\n\n\n\n
\"\"<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

CAMBRIDGE, Mass.<\/span><\/span>, Dec. 16, 2024<\/span><\/span> \/PRNewswire\/ — Nona Biosciences, a global biotechnology company providing a total solution from “Idea to IND” (I to ITM<\/sup>),\u00a0today\u00a0announced a research collaboration and license agreement to discover next-generation T-cell engagers (“TCEs”) with Candid Therapeutics, Inc. (“Candid”), a clinical-stage biotechnology company based in San Diego<\/span> and focused on becoming the leader in advancing TCEs for autoimmune diseases.<\/p>\n

\n<\/div>\n

Under the terms of the agreement, Nona Biosciences is eligible to receive up to $320 million<\/span>, including an upfront payment and potential milestone payments. Candid will be responsible for all further product development.<\/p>\n

“We are pleased to collaborate with Candid Therapeutics, a pioneer in advancing T-cell engagers for autoimmune diseases,” said Jingsong Wang<\/span>, MD, PhD, Chairman of Nona Biosciences. “T-cell engagers generated from our proprietary HBICE\u00ae<\/sup> technology platform offer several advantages, including precision targeting, flexible formats, enhanced efficacy and optimized safety profiles. Leveraging our industry-leading technology platforms, alongside our extensive expertise in antibody discovery and development, we look forward to supporting Candid in advancing innovative treatments and bringing new hope to patients.”<\/p>\n

“Nona Biosciences has an impressive discovery toolkit and we look forward to developing novel T-cell engagers through this collaboration,” said Ken Song<\/span>, MD, PhD, Chairman, President and CEO of Candid Therapeutics.<\/span><\/p>\n

About Nona Biosciences<\/b><\/p>\n

Nona Biosciences is a global biotechnology company committed to cutting edge technology innovation and providing a total solution from “Idea to IND” (I to ITM<\/sup>), ranging from target validation and antibody discovery through preclinical research. The integrated antibody and antibody-related discovery services with multiple modalities range from antigen preparation, animal immunization, single B cell screening, to antibody lead generation and engineering, developability assessment and pharmacological evaluation, leveraging advantages of Harbour Mice\u00ae<\/sup> platforms and the experienced therapeutic antibody discovery team.<\/p>\n

Harbour Mice\u00ae<\/sup> generates fully human monoclonal antibodies in classical two light and two heavy chain (H2L2) format, and heavy chain only (HCAb) format. Integrating Harbour Mice\u00ae<\/sup> and a single B cell cloning platform, Nona Biosciences is focused on driving global inventions of transformative next-generation drugs. For more information, please visit:\u00a0www.nonabio.com<\/a><\/u>.<\/p>\n

About Candid Therapeutics, Inc.<\/b><\/p>\n

Candid Therapeutics is a clinical-stage biotechnology company focused on becoming the leader in advancing T-cell engagers for B-cell depletion to treat autoimmune diseases. Candid is advancing two lead B-cell depleting TCE antibody drug candidates, with a goal to broadly explore the potential of TCEs across multiple autoimmune diseases by targeting different B-cell protein targets, as well as evaluating different depths of B-cell depletion. Established in 2024 and headquartered in San Diego, CA<\/span>, Candid is led by a team of entrepreneurial executives who have a track record of advancing programs into and through development and is supported by a distinguished syndicate of premier life science investors.<\/p>\n

<\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-15139","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/15139","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=15139"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/15139\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=15139"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=15139"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=15139"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}